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Carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) is a morphogen in an in vitro model for lumen
formation and plays a similar role in breast epithelial cells implanted in humanized mammary fat pads in NOD-SCID mice.
Although extra cellular matrix alone is suﬃcient to stimulate lumen formation in CEACAM1 transfected MCF-7 cells grown in
3D culture, there is an additional requirement for stromal or mesenchymal cells (MSCs) for these cells to form xenografts with
glandular structures in an orthotopic site. We demonstrate that optimal in vitro conditions include both Matrigel and MSCs and
that the inclusion of collagen I inhibits xenograft diﬀerentiation. Additionally, there is no need to remove the nascent murine
mammary gland. The previously observed diﬀerence in gland development between the long and short cytoplasmic domain
isoforms of CEACAM1 is no longer observed in pregnant NOD/SCID mice suggesting that stimulation of the mammary fat pad
by pregnancy critically aﬀects xenograft diﬀerentiation.
1.Introduction
Mammary gland development is critically dependent on
mesenchymal tissue [1, 2]. In the correct context, mammary
epithelialcellswilldevelopbranchedglandulartissuecapable
of milk production. In order to study human breast cancer
in an animal model, it is necessary to implant breast cancer
cells in an orthotopic site along with human stromal cells
and other components such as ECM. The identiﬁcation of
essential components for proper growth of breast cancer
epithelial cells was pioneered by Bissell and coworkers in
an in vitro model in which mammary epithelial cells are
grown in a 3D culture of extracellular matrix supplied by
Matrigel [3, 4]. However, this model lacks the contribution
of mesenchymal cells (MSCs) that are implicated in both
normal mammary gland development and breast cancer
[1, 5]. Recently, Kuperwasser et al. [6] developed an in vivo
model in NOD/SCID mice in which the nascent murine
mammary gland was removed and immortalized human
breast ﬁbroblasts were introduced to humanize the gland
prior to addition of human mammary epithelial cells. Other
components of the model include the use of radiation-
killed breast ﬁbroblasts, Matrigel, and collagen I. In our
own studies, we have found that the human mammary
epithelial cell line MCF7 that lacks CEACAM1 fails to
form glands with a lumen in the in vitro 3D model, while
transfection of CEACAM1 into MCF7 cells restores gland-
like formation [7]. Similarly, when wild type MCF7 cells
are grown in humanized mammary fat pads of NOD/SCID
mice, solid tumors are formed, while CEACAM1 transfected
MCF7 cells form glands with a lumen [8]. Surprisingly,
we found a diﬀerence in gland formation between the two
major isoforms of CEACAM1, namely, the short (forms no
glands) versus the long (forms glands) cytoplasmic domain
isoforms. This diﬀerence has led us to speculate that the
ratio of short to long isoforms in human breast may become
altered in breast cancer leading to the altered morphology
characteristic of ductal carcinoma in situ (DCIS) [9]. These
results have also prompted us to dissect the phosphorylation
status of the long and short cytoplasmic domains in further2 International Journal of Breast Cancer
experiments in the humanized mammary fat pad model [8,
10]. During the course of these studies, we began to question
the role of each of the components used in the humanization
of the murine mammary fat pad and the physiological status
of the gland.
In a comprehensive analysis of the model, we have found
that removal of the nascent murine mammary gland is not
required to obtain well-diﬀerentiated glandular xenograft
formation for CEACAM1 transfected MCF7 cells. We also
show that immortalized human MSCs can be used in place
of the immortalized breast ﬁbroblasts and that there is no
requirement for either collagen I or radiation-killed breast
ﬁbroblasts. However, the inclusion of Matrigel and MSCs
appears to be essential while the inclusion of collagen I
inhibits xenograft diﬀerentiation. Interestingly, the afore-
mentioned short isoform of CEACAM1 (CEACAM1-4S),
that failed to form glands in the original model, formed
glands in pregnant NOD/SCID mice, indicating that the
physiological status of the gland is also important.
T h er o l eo fM S C si nb r e a s tc a n c e rd e v e l o p m e n th a s
been recently explored by the Weinberg group [11]w h e r e
they demonstrated that MSCs can promote breast cancer
metastasis for certain breast cancer cell lines grown subcu-
taneously in mice. We show here that MSCs, in this case
immortalized MSCs, are not necessarily prometastatic as
predicted by Karnoub et al. [11], but instead can promote
diﬀerentiation and glandular development of epithelial cells
in the xenograft.
2.MaterialsandMethods
This study was approved by the City of Hope/Beckman
Research Institute Institutional Animal Care and Use Com-
mittee (IACUC) and Institutional Biosafety Committee
(IBC). All animal experiments were conducted in COH/BRI
Animal resource center, which is AAALAC accredited and is
in compliance with the Animal Welfare Act and the Guide for
the Care and Use of Laboratory Animals. Human fetal bone
marrow collection was approved by Institutional Review
Board (IRB).
2.1. Cell Cultures. Breast cancer cell lines, MCF-7, MDA-
MB-468 (MEM medium with L-glutamine, 10%FBS,
1% Sodium bicarbonate, 1% sodium pyruvate, and 1%
antibacterial-anti-mycotic solution), and DU4475 (RPMI-
1640 Medium supplemented with L-glutamine, 10% FBS,
and 1% antibacterial-anti-mycotic solution), were obtained
from American-type culture collection and SUM1315 cel-
lline (F-12 medium supplemented with L-glutamine, 10%
FBS,5μg/mLinsulin,and10ng/mLepidermalgrowthfactor,
and 1% antibacterial-anti-mycotic solution) was a gift from
Dr.MichaelRosenblatt,TuftsUniversity,SchoolofMedicine.
Selection of stable cell lines: transfection and selection of
MCF-7 cells with CEACAM1-4S or vector were previously
described [12].
2.1.1. Stromal Cell Lines. Immortalized breast ﬁbroblasts
(RMF/EG)wereagiftfromDr.Kuperwasser,TuftsUniversity
(DMEM medium supplemented with L-glutamine, 10% calf
serum, and 1% antibacterial and antimycotic solution) and
MSC cell line (alpha-MEM medium supplemented with
L-glutamine, 15% FBS, and 1% antibacterial-anti-mycotic
solution). To generate the MSC cell line, bone marrow
cells (MSCs) were obtained from human fetal long bone
and cells were ﬁltered through nylon mesh and grown in
60mm culture dishes with Modiﬁed Eagle medium alpha
(MEM-α) supplemented with 15% fetal bovine serum and
25mg/mL gentamicin (feeding medium). Primary MSCs
were immortalized with human telomerase (hTERT) in
the pBABE-neo-hTERTretroviral vector (addgene Inc). Poly-
clonal populations of immortalized MSCs (hTert MSC)
were selected through serial passages in media containing
neomycin. The hTERT MSCs were characterized by FACS
analysis for cell surface markers and were positive for CD44,
CD90,CD105,CD146,CD166,ALP,andSTRO-1.Thesecells
can diﬀerentiate in vitro into the adipocytes, chondrocytes,
myocytes, and osteoblasts depending on diﬀerentiation
media (data not shown).
2.2. In Vivo Studies. The breast cancer cells (0.2million cells)
and/or stromal cells (0.2 or 0.05million cells) in extracellular
matrix (50μL-Matrigel or Matrigel plus type 1 collagen
or PBS) were injected into orthotopic sites (humanized
orthotopic mammary fat pad site or mouse mammary
stroma (no clearing of fat pad and humanization)) of
NOD/SCIDmice.Thetotalnumberofanimalsineachgroup
was 8 and each animal has two xenografts, for a total of
16 xenografts. The results shown are representative of the
results.
2.2.1. Removal and Humanization of Mammary Fat Pad.
The humanized orthotopic mammary fat pad mouse model
developed by Kuperwasser et al. [6] was used except for the
substitution of single cell suspension for mammospheres,
and MSCs instead of immortalized human ﬁbroblasts.
Brieﬂy, three-to four-week-old NOD/SCID mice were anes-
thetized with isoﬂurane and placed on dorsal recumbency.
The abdominal and inguinal area was shaved and cleaned
with betadine and 70% alcohol. After disinfection of the
skin, small midline incision (1cm) close the fourth nipple by
small scissors was made. Forth inguinal mammary fat pads
were carefully excised using iris scissors (clearance of mouse
mammary fat pad) and the incision was closed with super
glue. Animals received analgesics (buprenorphine, s.c)a n d
antibiotics (Trimethoprim Sulfa in water) following surgical
procedures. Two weeks later, 2 × 105 unirradiated MSC cells
plus 2 × 105 irradiated MSCs (50× L in saline) were injected
intotheclearedmammaryfatpad(humanizationoffatpad).
Human breast cancer cells (2 × 105 cells) plus 2 × 105
MSCs in 50μL of collagen type I and matrigel mixture (3:1)
were injected into the humanized area. Then, mice would be
observed for tumor growth for 4–12 weeks and mice were
euthanized and the tumors were collected and examined for
morphology and expression of CEACAM1.
2.3. Human Breast Cancer Tissue Implantation. Human
breast tumor tissue for these experiments was procured
in compliance with NIH regulations and reviewed andInternational Journal of Breast Cancer 3
approved by Institutional Review Board (IRB#05091), City
of Hope National Medical Center. Deindentiﬁed tissue was
subjected to either enzymatic digestion (collagenase and
hyalurondinase, Stem cell technologies) to isolate epithelial
cellorganoidsaccordingtothemanufacturer’srecommenda-
tions or cut into the small pieces (0.1cm) to implant into the
orthotopic site of the NOD/SCID mice. In case of organoids,
20–25 human breast epithelial organoids were mixed with
2 × 105 hTert MSC in 50μL of Matrigel and injected into
the orthotopic site of NOD/SCID mice (four animals per
specimen). For breast cancer tissue implantation, three- to
four-week-oldNOD/SCIDmicewereanesthetized,surgically
prepared and cared for as indicated in Section 2.B r i e ﬂ y ,
small midline incision close to fourth nipple was made and
small piece (0.1cm) of breast tumor tissue was immersed
in Matrigel containing hTert MSC (1 × 106/mL) and placed
underneath the mammary fat pad (orthotopic site) and skin
incision was closed with superglue.
2.4. Histology. Xenografts were collected and ﬁxed in 10%
phosphate buﬀered formalin and subject to hematoxylin and
xyline (H and E) staining.
2.5. Statistical Analysis. Statistical signiﬁcances between the
groups were analyzed by One-way ANOVA (Tukey’s multiple
comparison test).
3. Results
3.1. Comparison of Xenograft Growth in an Orthotopic Site
with or without Nascent Glands. In the model described by
Kuperwasser et al. [6], the nascent mammary gland was
removed from the fat pad of NOD/SCID mice prior to
implantation of ﬁrst immortalized stromal cells followed
by implantation of stromal cells plus epithelial mammo-
spheres. Since many groups have implanted tumors at
the mammary fat pads without the prior removal of the
nascent mammary gland [13, 14], we ﬁrst investigated the
requirementfornascentglandremoval.Inourmodelsystem,
we utilized wild type or CEACAM1-4S transfected MCF7
(MCF7/CEACAM1) cells implanted as a single cell suspen-
sion rather than as mammospheres because we felt that
the preformation of mammospheres may already resemble
gland formation. Thus, we were interested in asking if, in the
correct environment, single cells could organize themselves
into gland-like structures without the prerequisite of mam-
mosphereformation.Exceptforthisonechange,wefollowed
the Kuperwasser model in one set of mice which had the
nascent murine mammary gland removed, inoculation with
viable plus irradiated stromal cells (hTert MSC) followed by
inoculation with MCF7 or MCF7/CEACAM1 cells plus the
mixture of stromal cells (hTert MSC) plus collagen I and
Matrigel(3:1mixture)(seeTable 1 forexperimentaldetails).
In the other set of animals, the nascent murine mammary
gland was not removed. Thus, these mice directly received
MCF7 or MCF7/CEACAM1 cells plus the mixture of stromal
cells plus collagen I and Matrigel (3:1).
Human xenografts from the humanized mammary fat
pad model were palpable around 10–12 weeks for both
MCF7 and MCF7/CEACAM1 xenografts. When the mice
wereeuthanizedandtheskindissected,weobservedtheclose
association of the xenograft and the nascent mammary fat
pad. However, the xenograft tissue was distinct from the
murine mammary fat pad, indicating that the two tissues
were not comingled. Histological examination of MCF7
xenografts revealed solid tumors (poorly diﬀerentiated car-
cinoma) without any evidence of higher organization or
diﬀerentiation and with very little incorporation of extra-
cellular matrix (Figure 1(a)). In contrast, MCF7/CEACAM1
xenografts were organized and diﬀerentiated into a striated
epithelium-likestructurewithabundantextracellularmatrix
between the cells, resembling moderately diﬀerentiated car-
cinoma (Figure 1(b)). These results are identical to those
previously published by us in this model [8] with the
diﬀerence that hTert/MSC cell line was used in place of
immortalized human breast ﬁbroblasts (RMF/EG). In the
case of xenografts in which the nascent mammary gland
was not removed, the xenografts grew more rapidly and
were palpable within 8 weeks (Figures 1(c) and 1(d)).
MCF7 and MCF7/CEACAM1 xenografts were of similar
size and had the same histological features as xenografts
from the humanized mammary fat pad model. To conﬁrm
that xenografts were originated from human cells and
not comingled with the mouse mammary tissue, we per-
formed immunohistochemistry on the histological section
with human cytokeratin antibody and human CEACAM1
antibody as previously described in our paper [8], and all
xenografts stained positive for human cytokeratin while only
MCF7/CEACAM1 xenografts stained positive for human
CECAM1 (data not shown). These results indicate that the
MCF7 cells (with or without CEACAM1) grow equally well
in the orthotopic sites of both humanized mammary fat
pad and nascent mouse mammary pad of NOD/SCID mice
and have identical histological features. Thus, at least in this
model, there is no need to remove the nascent mammary
gland. In the humanized mammary fat pad model, not only
is surgery required for removal of the nascent mammary
gland followed by two weeks of recovery, humanization
with human stromal cells for two weeks is also required
followed by 10–12 weeks for growth of xenografts. Thus, a
t o t a lo f1 6 – 1 8w e e k si sr e q u i r e dp e ra n i m a lp e re x p e r i m e n t .
In contrast, xenograft growth at the orthotopic site of the
unresected mouse mammary fat pad requires only 6–8 weeks
for collection of xenografts.
3.2. Xenografts Using other Breast Cell Lines and Human
Breast Cancer Tissue. To examine whether breast cancer
cell lines other than MCF-7 would grow in unresected
mammary fat pads, we established xenografts using MDA-
MB-468 [15], SUM1315 [16], and DU4475 [17]b r e a s t
cell lines. Xenografts were collected at 8 weeks or when
outgrowth observed. We found that all three breast cancer
cell lines formed palpable tumors within 4–6 weeks, and
interestingly, the DU4475 cell line took only 3-4 weeks
for tumor outgrowth (>10mm). Histological examination
of these tumors revealed that DU4475 and MDA-MB-468
tumors incorporated extracellular matrix and had some
degree of organization (Figures 2(b) and 2(c)). In particular,4 International Journal of Breast Cancer
Table 1: Requirement for preparation of mammary gland.
MEC 1 SC2 ECM N3 x/T4 Outcome
Humanized mammary fat pads
MCF7 (2 × 105) hTert MSC (2 × 105) Col I plus matrigel (3:1) 8 0/16 Solid tumor
MCF7/CEACAM1-4S
(2 × 105)
hTert MSC (2 × 105) Col I plus matrigel (3:1) 8 14/16∗ Diﬀerentiation into striated epithelium
Normal mouse mammary fat pads
MCF7 (2 × 105) hTert MSC (2X105) Col I plus matrigel (3:1) 8 0/16 Solid tumor
MCF7/CEACAM1-4S
(2 × 105)
hTert MSC (2X105) Col I plus matrigel (3:1) 8 14/15∗ Diﬀerentiation into striated epithelium
1Mammary epithelial cell line (number of cells injected), 2Stromal cell line (number of cells injected), 3Number of animals, 4Number of xenografts exhibiting
striated epithelial structure (x)/Total number of xenografts (T), ∗indicates statistical signiﬁcance (P<. 01) for diﬀerentiation of xenografts, when compared
with control group (MCF7).
(a) (b)
(c) (d)
Figure 1: Comparison of human mammary xenograft formation by MCF-7 and MCF7/CEACAM1 in either humanized mammary fat pad
or nascent mammary fat pad in NOD/SCID mice. Gross pictures (left panels) of human xenografts and corresponding H and E stained
sections (right panels) of MCF7 xenografts (a) in humanized mammary fat pads or (b) MCF7 xenografts in nascent mouse mammary fat
pads)or(c)MCF7/CEACAM1xenograftsinhumanizedmammaryfatpadsor(d)MCF7/CEACAM1xenograftsinnascentmousemammary
fat pads. Magniﬁcation 200x.
DU4475tumorcellswereorganizedintosmallclusterswitha
nesty pattern separated by extracellular matrix (Figure 2(c)).
Similar to the DU4475 xenografts, MDA-MB-468 xenografts
were palpable around 6 weeks with no organization of
tumor cells with extracellular matrix. In contrast, xenografts
from SUM1315 cells grew as solid tumors (poorly diﬀer-
entiated carcinoma) without incorporation of extracellular
matrix and with good vascularization (Figure 2(a)). When
human breast xenografts were isolated eight weeks after
implantation of either epithelial organoids or small slices
of breast tumor tissue at mammary fat pads of NOD/SCID
mice, xenograft outgrowths were observed. The xenografts
from epithelial organoids were small (1-2mm), highly
vascularized, and consistently produced tumor outgrowths
with features of ductal carcinoma in situ (Figure 2(d)).
In the case of breast tumor tissue slice implantation,
xenografts were larger (4-5mm) with features of invasive
carcinoma (Figure 2(e)). These observations indicated that
human breast tissues or human breast cancer cell lines
with appropriate stromal environment can be grown in an
orthotopic site of NOD/SCID mice.
3.3. Eﬀect of ECM and Stromal Cells on Xenograft Growth.
Oneoftheunexplainedfeaturesofthehumanizedmammary
fat pad model is the requirement for both Matrigel and
collagen I during the engraftment of the breast cancer
epithelial cells. It should be noted that the 3D model
of mammary morphogenesis developed by Lee et al. [3]
contains Matrigel and no collagen I. In fact, collagen I is





fat pad of NOD/SCID mice. Gross pictures of human xenografts (left panels) and corresponding H AND E stained sections of xenografts
(rightpanels)frombreastcancercelllinesorhumanbreasttissueimplantation(a)SUM1315,(b)MDA-MB-468,(c)DU4475(Magniﬁcation
200x), (d) human breast epithelial organoids (Magniﬁcation 400x), and (e) human breast tumor slices (Magniﬁcation 200x).
collagen IV) and its inclusion in the engraftment protocol is
unexpected. In addition, the requirement for both stromal
cells and ECM is unexplained; that is, if stromal cells can
produce their own ECM, why is there a need for exogenous
ECM? To determine if the mixture of Matrigel plus collagen
I inﬂuences the organization and diﬀerentiation of the
mammary epithelial cells into glandular structures, MCF7
cells (or MCF7/CEACAM1) with no ECM, Matrigel alone or
collagen I plus Matrigel (3:1) were inoculated into nascent
mammary fat pads along with stromal cells (see Table 2 for
experimental details). First, we found that implantation of
either cell line with no ECM resulted in low engraftment of
xenografts, where only three out of eight animals developed
tumors and xenografts that were small (<1-2mm) compared
to xenografts from mice that received ECM (Figure 3(a)).
Histological examination of these xenografts revealed that
there was no high level of organization or diﬀerentiation
of MCF7/CEACAM1 cells with very little ECM between the
cells, whereas xenografts that included ECM were organized
into striated epithelium and had abundant ECM. These
results demonstrate that ECM is necessary for engraftment
and diﬀerentiation of xenografts.
Next we addressed the issue of stromal cell requirement.
MCF7/CEACAM1 xenografts in which ECM included col-
lagen I with no stromal cells engrafted; however, xenografts
were small and there was no diﬀerentiation or organization
of epithelial cells into striated epithelium (Figure 3(c)).
Moreover,MCF7/CEACAM1cellsinMatrigelalone(nostro-
mal cells) also engrafted, and although the size of xenografts
was small (<1-2mm), the omission of collagen I from the
ECM mixture promoted mammary epithelial cell diﬀerenti-
ation into solid acini formation lacking lumen, resembling
hyperplastic normal mammary gland (Figure 3(b)). These
results indicate that inclusion of stromal cells is necessary
for expanded growth of xenografts and that ECM is required
for engraftment and initial diﬀerentiation of the epithelial
cells. In addition, the composition of ECM inﬂuences the
organization and degree of diﬀerentiation of the epithelial
cells, but in which the inclusion of collagen I inhibits the
further diﬀerentiation of epithelial cells into acini with
lumen. Thus, stromal cells and ECM are necessary for
optimal growth and diﬀerentiation of human xenografts.
Based on these results, we used Matrigel alone with no
collagen I for further experiments.6 International Journal of Breast Cancer
Table 2: Eﬀect of extracellular matrix on diﬀerentiation of xenografts.
MEC 1 SC2 ECM N3 x/T4 Outcome
None hTert MSC (2 × 105) Matrigel orCol I plus matrigel (3:1) 8 — No growth or no xenogratfs
MCF7 (2 × 105) None Col I plus matrigel (3:1) 8 0/16 Solid tumor
MCF7/CEACAM1-4S
(2 × 105)
None Col I plus matrigel (3:1) 8 0/16 Solid tumor and no diﬀerentiation
MCF7 (2 × 105) hTert MSC (2 × 105) None 8 0/4 Solid tumor and low engraftment
MCF7/CEACAM1-4S
(2 × 105)
hTert MSC (2 × 105) None 8 0/3 Solid tumor and low engraftment
MCF7 (2 × 105) None Matrigel 8 0/16 Solid tumor
MCF7/CEACAM1-4S
(2 × 105)
None Matrigel 8 15/16∗ Diﬀerentiation into acini
1Mammary epithelial cellline (number of cells injected), 2Stromal cell line (number of cells injected), 3Number of animals, 4Number of xenografts exhibiting
gland-like structures (x)/Total number of xenografts (T), ∗indicates statistical signiﬁcance (P<. 01) for diﬀerentiation of xenografts, when compared with all
other groups in this table.
(a) (b) (c)
Figure 3: Eﬀe c to fE C Ma n ds t r o m a lc e l l so ng r o w t ha n dd i ﬀerentiation of MCF7/CEACAM1 xenografts. Gross pictures of human
xenografts (left panels) and corresponding H AND E stained sections of xenografts (right panels) containing MCF7/CEACAM1 cells in
mouse mammary fat pad with (a) hTert/MSC and no ECM, (b) ECM (Matrigel alone) and no stromal cells, and (c) ECM ( Collagen 1 and
Matrigel 3:1 ratio) and no stromal cells. Magniﬁcation 200x.
3.4. Eﬀect of Stromal Cell Type on the Model System. In the
original study of Kuperwasser et al. [6], an immortalized
human breast ﬁbroblast cell line (RMF/EG) was used as
the source of stromal cells. In later studies, Weinberg
and coworkers [11] studied the eﬀect of bone marrow
derived mesenchymal stem cells (MSCs) on the growth and
metastatic behavior of breast cancer cell lines. Both the
requirementforandthesourceofthestromalcells,including
their ultimate eﬀects on the model system, are relatively
unexplored. In order to address this issue, we developed a
human bone marrow derived MSC cell line (hTert/MSC)
and tested its ability to substitute for the RMF/EG cells used
in the original model. The morphology of the hTert/MSC
cell line was typical of stromal cells (Figure 4(a)). A major
impetus for substituting hTert/MSC cells for RMF/EG cells
was that they do not required the addition of irradiated
stromal cells, a requirement that was unexplained in the
model of Kuperwsser et al. [6].
The hTert/MSCs (hTert/MSC to MCF7/CEACAM1 at a
ratio: 1:4 or 1:1) or immortalized human breast ﬁbroblasts
(RMF/EG to MCF-7 or MCF7/CEACAM1 ratio: 1:1) in
Matrigel (no collagen I) were implanted into mammary fat
pads (no prior humanization) (see Table 4 for experimental
conditions). hTert MSCs (both ratios) promoted growth of
the epithelial cells in the xenografts; however, xenografts
from 1:1 hTert MSC: MCF7/CEACAM1 cell ratio had more
extracellular matrix between the glandular structures and
had the appearance of ductal hyperplasia (Figures 5(a)
and 5(b)). Notably, xenografts with a hTert/MSC:epithelial
ratio of 1:4 had decreased ECM and diﬀerentiation ofInternational Journal of Breast Cancer 7
Table 3: Characterization and optimization of an in vivo mammary gland morphogenesis model1.
MEC Stromal cells ECM Outcome
Humanized mammary fat pads
None hTert MSC ECM or None No growth
+ hTert MSC Col I plus matrigel Slow growth of xenografts (>10 weeks) and diﬀerentiation into striated epithelium
Normal mouse mammary fat pads
+ hTert MSC Col I plus matrigel Rapid xenograft growth (≤8 weeks) and diﬀerentiation into striated epithelium
+ hTert MSC None Low engraftment (3 out 8 animals) and lack of diﬀerentiation
+ None Col I plus matrigel Small xenografts (<1-2mm) and lack of diﬀerentiation
+ None Matrigel Small xenografts (<1-2mm), but formation of acni and clusters of cells
+ RMF/EG Matrigel/No ECM Larger xenografts (>5–10mm), but outgrowth of ﬁbroblasts
+ hTert MSC Matrigel Growth of xenografts (>5mm) and diﬀerentiation epithelial cells
Pregnant mammary fat pads
+ hTert MSC Matrigel Growth of xenografts (>5mm) and formation of lumen
1+ indicates MCF-7 transfected with CEACAM1-4S.
Table 4: Eﬀect of type and number of stromal cells on diﬀerentiation of xenografts.
MEC 1 SC2 ECM N3 x/T4 Outcome
MCF7 (2 × 105)h T e r t M S C ( 2 × 105) Matrigel 8 0/16 Solid tumor
MCF7/CEACAM1-4S (2 × 105)h T e r t M S C ( 2 × 105) Matrigel 8 15/16∗ Diﬀerentiation into gland like structures
MCF7/CEACAM1-4S (2 × 105)h T e r t M S C ( 5 × 104) Matrigel 8 16/16∗ Diﬀerentiation into gland like structures
MCF7/CEACAM1-4S (2 × 105) RMF/EG (2 × 105) Matrigel 8 0/16 Fibrosarcoma
MCF7 (2 × 105) RMF/EG (2 × 105) Matrigel 8 0/16 Fibrosarcoma
1Mammary epithelial cell line (number of cells injected), 2Stromal cell line (number of cells injected); 3Number of animals, 4Number of xenografts exhibiting
gland-(acinar-)likestructures(x)/Totalnumberofxenografts(T), ∗indicatesstatisticalsigniﬁcance(P<. 01)fordiﬀerentiationofxenografts,whencompared
with control group (MCF7).
Figure 4: Morphology of hTert/MSC cell line. Phase contrast
photograph of hTert/MSC cells grown on plastic.
epithelial cells into ducts ﬁlled epithelial cells, suggesting
that a ratio of ≥1 should be used. Although human breast
ﬁbroblast (RMF/EG) containing xenografts grew faster
(palpable within 4 weeks) and larger than the xenografts
with hTert/MSCs (10mm versus 5mm), histological exam-
ination revealed the overgrowth of ﬁbroblasts and the
lack of proliferation of epithelial cells, for both MCF7
and MCF7/CEACAM1 (Figures 5(c) and 5(d)). Impor-
tantly, implantation of RMF/EG immortalized human breast
ﬁbroblasts alone also led to the formation of ﬁbrosarcomas
but this did not occur for hTert/MSCs (data not shown).
3.5. Eﬀect of Physiological Status of the Mammary Gland on
Xenografts. Murine mammary glands are maintained in a
physiologic nascent state until pregnancy. Once the animal
is pregnant the gland rapidly expands in size, increasing the
number of ducts and alveolar structures [18]. In humans,
the breast is more developed following puberty than in mice,
raising the possibility that major functional diﬀerences are
likely between murine and human postpubescent mammary
glands. Since the physiologic status of the gland is expected
to have an impact on the growth of implanted xenografts
[19, 20], it was important to test our ﬁnal model in
pregnant mice as a surrogate for a postpubescent human
mammary gland. To understand the impact of pregnancy on
xenografts formation and diﬀerentiation, MCF7/CEACAM1
cells along with hTert MSC in matrigel were transplanted
intoinguinalmammaryglandofeight-week-oldNOD/SCID
mice; mice were mated immediately and then xenografts
were collected after the weaning of pups. These xenografts
were well vascularized and histological examination revealed
formation of well-diﬀerentiated glands with a central lumen
(Figures 6(a) and 6(b)). These results demonstrate the
importance of physiological status of in vivo system on the
diﬀerentiation of the xenografts.
In summary, we examined the role of stromal cells and
ECM in the human xenograft growth and breast cancer
epithelial cell diﬀerentiation. We found that nascent mam-
maryglandremovalanditshumanizationwerenotnecessary
for growth and diﬀerentiation of human xenografts, and8 International Journal of Breast Cancer
(a) (b)
(c) (d)
Figure 5: Eﬀect of type and number of stromal cells on the growth and diﬀerentiation of MCF7 and MCF7/CEACAM1 xenografts. Gross
pictures of human xenografts (left panels) and corresponding H and E stained sections of xenografts (right panels) with hTert/MSC or
immortalized breast ﬁbroblasts (RMF/EG) and diﬀerent ratios of epithelial cells: stromal cells. (a) hTert/MSC:MCF/CEACAM1 ratio 1:4 in
Matrigel, (b) hTert/MSC:MCF7/CEACAM1 ratio 1:1 in Matrigel, (c) RMF/EG along with MCF7/CEACAM1 in Matrigel (1:1 ratio), and
(d) RMF/EG along with MCF7 in Matrigel. Magniﬁcation 200x.
(a) (b)
Figure 6: Eﬀect of physiological status of the mammary gland on
growth and diﬀerentiation of xenografts. MCF7/CEACAM1 cells
along with hTert/MSC (1:1 ratio) in Matrigel were implanted
into the inguinal mammary fat pads of eight-week-old female
NOD/SCID mice and immediately mated to induce the pregnancy
to change the physiological status of mammary gland. After
weaning of pups, (a) xenografts were collected and (b) H and
E staining performed on sections from xenografts. Magniﬁcation
200x.
MSC and ECM were required for the growth and engraft-
ment of xenografts. ECM composition is also important
for diﬀerentiation and organization of mammary epithelial
cells, and presence of Collagen I inhibits diﬀerentiation of
epithelial cells (summarized in Table 3).
4. Discussion
Although considerable progress has been made in the
development of an in vitro 3D model of human mammary
morphogenesis, the 3D model lacks the physiological setting
of a live animal that includes features such as the cellular
components of the immune system and angiogenesis, or
hormonal inﬂuences from the endocrine glands, ovary, and
the mammary gland itself. The recently developed model of
Kuperwasser in which the mammary glands of NOD/SCID
micewere“humanized”wasamajorstepforwardpermitting
the growth of human mammospheres in a more physio-
logical setting [6]. However, this model requires complete
removal of the nascent mammary gland, takes a long time
to establish the “humanized” gland with both radiation-
killed and live-immortalized stromal cells, involves both
Matrigel and type I collagen, and utilizes mammospheres
rather than single-cell suspensions to establish new glands.
We have examined each of these features and developed a
morestreamlinedmodelthatgreatlyspeedsthedevelopment
ofxenografts(4–8 weeks versus16–18 weeks).Otherfeatures
of our improved model include the retention of the nascent
murine mammary gland, obviating the need to wait for the
repopulation of the mammary fat pad by human stromal
cells. We found that the xenografts grow as solid tumors with
no evidence of comingling with the nascent murine mam-
mary gland. When the skin was peeled back at the end of 4–8
weeks of growth, we found that the xenografts adhered to
the inner surface, while histological analysis revealed varying
degrees of tissue organization depending on the presence or
absence of stromal cells and Matrigel. Importantly, while the
inclusion of type I collagen in the matrix appeared to inhibit
overgrowth of the RMF/EG stromal cells, the use of an MSC
cell line obviated the need for collagen I and resulted in
xenografts that were comprised primarily of epithelial cells.
Nonetheless, both stromal cells and Matrigel are required for
proper establishment of xenografts, emphasizing the critical
role of ECM in the development of mammary glandular
tissue.International Journal of Breast Cancer 9
MCF7 cells are weakly tumorigenic and do not grow
well in subcutaneous transplants unless the mice are treated
with estrogen [21]. However, this cell line can be an
attractive model for studying breast cancer because reintro-
duction of genes such as CEACAM1 can cause reversion
to a more normal phenotype [7, 8]. For example, the
degree of diﬀerentiation of the mammary epithelial glands
depends on the expression of critical morphogens such
as CEACAM1 [8]. MCF cells lacking CEACAM1 always
produced solid tumors in either the original “human-
ized” mammary fat pads of Kuperwasser et al. [6]o ri n
the improved model described here. In contrast, MCF7
cells transfected with CEACAM1 produced either stri-
ated or single-layered epithelial sheets, depending on the
physiological environment. The dramatic conversion of
multilayered epithelial sheets to single-layered mammary
glands required pregnancy, emphasizing the role of hor-
monal status in developing mammary glands. The resulting
mammary glands were surrounded by ECM suggesting
that ECM production by stromal cells is also depen-
dent on the physiological status of the tissue. In non-
pregnant mice, less ECM was produced and the mam-
mary epithelial cells were multilayered, suggesting that
a communication program exists between the epithelial
and stromal cells that is context dependent. The con-
text probably includes, among other hormones, the pro-
duction of prolactin by the pituitary in the pregnant
mouse. Notably, pituitary extract is a critical component
of the in vitro 3D model of mammary morphogenesis
[3, 4].
The extension of the model to other breast cancer
cell lines as well as fresh breast cancer tissue was also
demonstrated. In each case, the xenografts developed neo-
vascularization, indicating that they had retained their
angiogenic programming. Thus, the model has general
utility for producing large amounts of tissue for further
analysis.
In summary, the improved in vivo model allows the
expansion of single-cell suspensions of mammary epithelial
cells in a nascent murine mammary gland into a pal-
pable xenograft within 4–8weeks. This model uses fewer
numbers of epithelial cells (0.2million per xenograft) and
allows them to establish, proliferate, and diﬀerentiate in the
orthotopic site, which mimics mammary gland develop-
ment and morphogenesis. The model requires Matrigel and
MSCs for full engraftment, but does not require radiation-
killed stromal cells, nor collagen I, thus preventing the
undesirable overgrowth of stromal cells into ﬁbrosarcomas.
The improved model further allows the observation of
xenograft growth in the presence or absence of pregnancy,
thusprovidingadditionalinsightsintotheeﬀectofhormonal
changes on xenograft development. Notably, our model was
optimized for study of both mammary gland neoplasia
and mammary gland morphogenesis. This model will allow
us to evaluate the eﬀect of adding in lymphocytes under
inﬂammatory conditions to mimic the eﬀect of chronic
inﬂammation on human mammary cell diﬀerentiation
or to test the eﬀect of various treatments on tumor
development.
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